Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11157
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrossmann, Mathisen
dc.contributor.authorZajac, Jeffrey Den
dc.date.accessioned2015-05-16T00:44:40Z
dc.date.available2015-05-16T00:44:40Z
dc.date.issued2011-03-01en
dc.identifier.citationClinical Endocrinology; 74(3): 289-93en
dc.identifier.govdoc21092052en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11157en
dc.description.abstractAdverse effects of androgen deprivation therapy (ADT) are a consequence of the induced sex steroid deficiency. ADT increases fat mass leading to insulin resistance and diabetes, and accelerates bone loss causing increased fracture risk. Given the high prevalence of cardiovascular disease and reduced bone density in ADT-naïve men with prostate cancer, the benefits of ADT have to be carefully weighed against its side effects, especially as a diagnosis of prostate cancer does not alter the life expectancy for most men. Men commencing ADT should be counselled about and be carefully monitored for these and other ADT-induced complications, which include fatigue, sexual dysfunction, hot flushes and anaemia. ADT-associated side effects should be prevented and treated in order that ADT-induced toxicity does not outweigh its benefits. Future clinical trials are needed: first, to better define the effects of ADT on survival in men with localized prostate cancer or with biochemical prostate-specific antigen recurrence; second, to delineate ADT-associated harm, especially with respect to cardiovascular events and fractures; and third, to test the efficacy of interventions designed to minimize ADT-related adverse outcomes. Such information will be essential to better quantify the risk-benefit ratio of ADT in the individual man with prostate cancer.en
dc.language.isoenen
dc.subject.otherAndrogen Antagonists.adverse effects.therapeutic useen
dc.subject.otherAntineoplastic Agents, Hormonal.adverse effects.therapeutic useen
dc.subject.otherCardiovascular Diseases.diagnosis.prevention & controlen
dc.subject.otherDrug-Related Side Effects and Adverse Reactions.diagnosis.prevention & controlen
dc.subject.otherFractures, Bone.prevention & controlen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherProstatic Neoplasms.drug therapyen
dc.subject.otherQuality of Lifeen
dc.subject.otherRisk Assessmenten
dc.subject.otherRisk Factorsen
dc.subject.otherTreatment Outcomeen
dc.titleAndrogen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical Endocrinologyen
dc.identifier.affiliationDepartment of Medicine, Austin Health/Northern Health, University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1111/j.1365-2265.2010.03939.xen
dc.description.pages289-93en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/21092052en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Feb 5, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.